The role of infection and comorbidity: Factors that influence disparities in sepsis

Objective:Large healthcare disparities exist in the incidence of sepsis based on both race and gender. We sought to determine factors that may influence the occurrence of these healthcare disparities, with respect to the source of infection, causal organisms, and chronic comorbid medical conditions. Design:Historical cohort study. Setting:U.S. acute care hospitals from 1979 to 2003. Patients:Hospitalized patients with a diagnosis of sepsis were identified from the National Hospital Discharge Survey per codes of the International Statistical Classification of Diseases, Ninth Revision (ICD-9CM). Chronic comorbid medical conditions and the source and type of infection were characterized by corresponding ICD-9CM diagnoses. Interventions:None. Measurements and Main Results:Sepsis incidence rates are mean cases per 100,000 after age adjustment to the 2000 U.S. Census. Males and nonwhite races were confirmed at increased risk for sepsis. Both proportional source distribution and incidence rates favored respiratory sources of sepsis in males (36% vs. 29%, p < .01) and genitourinary sources in females (35% vs. 27%, p < .01). Incidence rates for all common sources of sepsis were greater in nonwhite races, but proportional source distribution was approximately equal. After stratification by the source of infection, males (proportionate ratio 1.16, 95% confidence interval 1.04–1.29) and black persons (proportionate ratio 1.25, 95% confidence interval 1.18–1.32) remained more likely to have Gram-positive infections. Chronic comorbid conditions that alter immune function (chronic renal failure, diabetes mellitus, HIV, alcohol abuse) were more common in nonwhite sepsis patients, and cumulative comorbidities were associated with greater acute organ dysfunction. Compared with white sepsis patients, nonwhite sepsis patients had longer hospital length of stay (2.0 days, 95% confidence interval 1.9–2.1) and were less likely to be discharged to another medical facility (30% whites, 25% blacks, 18% other races). Case-fatality rates were not significantly different across racial and gender groups. Conclusions:Healthcare disparities exist in the incidence of sepsis within all major sources of infection, and males and blacks have greater frequency of Gram-positive infections independent of the infection source. The differential distribution of specific chronic comorbid medical conditions may contribute to these disparities. Large cohort and administrative studies are required to confirm discrete root causes of sepsis disparities.

[1]  D C Angus,et al.  Using large-scale databases to measure outcomes in critical care. , 1999, Critical care clinics.

[2]  I. Chaudry,et al.  Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. , 2001, Cytokine.

[3]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[4]  J. Sunderram,et al.  Facing the challenge: Decreasing case fatality rates in severe sepsis despite increasing hospitalizations* , 2005, Critical care medicine.

[5]  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.

[6]  G. Martin,et al.  The ICD-9 code for septicemia maintains a high positive predictive value for clinical sepsis , 2002 .

[7]  R. Bone,et al.  Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome) , 1992, JAMA.

[8]  I. Chaudry,et al.  The aromatase inhibitor, 4-hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis. , 2000, Shock.

[9]  Corinne Alberti,et al.  Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study , 2002, Intensive Care Medicine.

[10]  W. Knaus,et al.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.

[11]  A. Schäffer,et al.  A microsatellite polymorphism in intron 2 of human Toll-like receptor 2 gene: functional implications and racial differences. , 2004, FEMS immunology and medical microbiology.

[12]  F Doyon,et al.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. , 1995, JAMA.

[13]  R. Rossaint,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005, The New England journal of medicine.

[14]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[15]  G. Rothe,et al.  Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: Gender-specific genetic predisposition to sepsis , 2001, Critical care medicine.

[16]  R. Huth,et al.  Gender-based differences in children with sepsis and ARDS: The ESPNIC ARDS Database Group , 2003, Intensive Care Medicine.

[17]  R. Holman,et al.  Decline in Sepsis-associated Neonatal and Infant Deaths in the United States, 1979 Through 1994 , 1998, Pediatrics.

[18]  B. Guidet,et al.  Incidence and impact of organ dysfunctions associated with sepsis. , 2005, Chest.

[19]  Susan L Ettner,et al.  Contribution of major diseases to disparities in mortality. , 2002, The New England journal of medicine.

[20]  Adrienne Y. Stith,et al.  Unequal treatment: confronting racial and ethnic disparities in health care. , 2003 .

[21]  R. Schwartz.  Racial profiling in medical research. , 2001, The New England journal of medicine.

[22]  D. Bates,et al.  Epidemiology of sepsis syndrome in 8 academic medical centers. , 1997, JAMA.

[23]  U. Steckholzer,et al.  Incidence of septic complications and multiple organ failure in severely injured patients is sex specific. , 2000, The Journal of trauma.

[24]  S. Opal,et al.  High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .

[25]  V. Sundararajan,et al.  Epidemiology of sepsis in Victoria, Australia , 2005, Critical care medicine.

[26]  J. Johnston,et al.  Importance of organ dysfunction in determining hospital outcomes in children. , 2004, The Journal of pediatrics.

[27]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[28]  Duncan Young,et al.  Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland , 2003, Critical care medicine.

[29]  J. le Gall,et al.  Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. , 2005, American journal of respiratory and critical care medicine.

[30]  M. Kaminishi,et al.  Gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating LPS-induced cytokine secretion in an ex vivo septic model. , 2001, Shock.

[31]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[32]  F. Stüber,et al.  Gender differences in sepsis: genetically determined? , 2000, Shock.

[33]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[34]  C. Sprung,et al.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. , 2003, JAMA.

[35]  D. Pittet,et al.  Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients , 1993, Intensive Care Medicine.

[36]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[37]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[38]  François Gouin,et al.  Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults: A Multicenter Prospective Study in Intensive Care Units , 1995 .

[39]  Epidemiology of sepsis syndrome in 8 academic medical centers. , 1997 .

[40]  G. Martin,et al.  A global perspective on the epidemiology of sepsis , 2004, Intensive Care Medicine.

[41]  G. Oster,et al.  Is sepsis accurately coded on hospital bills? , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[42]  ROBERT W. Johnson,et al.  Healthy people. , 1985, Canadian journal of public health = Revue canadienne de sante publique.

[43]  Corinne Alberti,et al.  Determinants of postintensive care unit mortality: A prospective multicenter study , 2003, Critical care medicine.

[44]  Gilles Clermont,et al.  The epidemiology of severe sepsis in children in the United States. , 2003, American journal of respiratory and critical care medicine.

[45]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[46]  S. Opal,et al.  Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? , 1999, Critical care medicine.